Abstract A072: Genetic ancestry is related to potential sources of breast cancer health disparities among Colombian women

• Published in: Cancer epidemiology, biomarkers & prevention biomarkers & prevention, 2023-01, Vol.32 (1_Supplement), p.A072-A072
• Main Authors: Serrano-Gómez, Silvia J., Rey-Vargas, Laura, Bejarano, Lina, Mejía-Henao, Juan Carlos, Sanabria-Salas, Maria Carolina
• Format: Article
• Language: English
• ISSN: 1538-7755; 1538-7755
• DOI: 10.1158/1538-7755.DISP22-A072

Introduction: Socioeconomic disadvantages can contribute to breast cancer health disparities among populations. However, it has been shown that other factors related to the etiology of breast cancer and the biology of the tumor, might also act as determinants of health disparities, as they can impact the patients’ treatment. To date, the relationship between these factors with genetic ancestry in a highly admixed population from Latin-America, has not yet been explored. Based on this, we aimed to assess contributing factors to breast cancer health disparities according to genetic ancestry in Colombian patients from a national cancer reference center. Methods: We revised clinical-pathological and socioeconomic data from breast cancer patients diagnosed at the National Cancer Institute (NCI) of Colombia and classified variables into the following groups: etiology-related factors (e.g., age of diagnosis), tumor-biology factors (e.g., tumor size), and socioeconomic factors (e.g., health insurance), each of which reflects potential sources of racial/ethnic disparities of breast cancer. We also considered variables related to treatment administration (e.g., neoadjuvant therapy) as an indicator of disease management. We applied a Kruskal–Wallis test to assess differences in genetic ancestry fractions according to each of the variables distribution. Results: A total of 308 Colombian breast cancer patients were included. Etiology-related factors analysis showed higher European ancestry fraction in patients diagnosed at older ages (>50 years: 50% vs. ≤50 years: 46%, p=0.017), and with smaller tumors (